Negative trend sustained, but there are a few growth options in H2 We cut adj.
Redeye comments on q.beyond’s Q2 report showing a slightly more substantial improvement in EBITDA an...
Redeye presents its preview for Paxman’s Q2 2025 report, due on August 20.
Vi inleder bevakning på mResell, en ledande svensk aktör inom re-commerce som specialiserar sig på r...
Redeye notes a soft Q2 on both sales and EBIT, and we expect a negative share price reaction today o...
Redeye negatively views Surgical Science’s profit warning for Q2 2025.
SRV's net sales in Q2 amounted to EUR 168.7m, slightly below our estimate of EUR 174.
Suominen faced another setback on its earnings recovery path as US volumes were missing big time.
DT’s Q2 earnings were softer than estimated and disappointingly Q3 results too are about to decline,...
Redeye updates on G5 after weaker-than-expected Q2-results which have resulted in lowered estimates.
Redeye provides an update following Optomed’s Q2 2025 report.
Suominen's Q2 report fell clearly short of Vara Research consensus expectations owing to very weak v...
Prospekterings- och gruvutvecklingsbolaget Bluelake Mineral fick planförslag och reguleringsplan för...
Rottneros reports SEK 140m impairment ahead of Q2 Challenging markets for Rottneros and Arctic Paper...
Adj. EBIT -29% vs FactSet consensus; FX adj sales -11% y-o-y Estimates to come down 8-10% on slower ...
Suominen Q2 comparable EBITDA of EUR 3.2m came clearly below Vara Research consensus expectation of ...
Redeye notes that BeammWave’s Q2 2025 report delivered a surprise, with the company posting net sale...
DT’s Q2 revenue was slightly higher than expected, however the EUR 1.
Etteplan’s H1 was disappointing, with the escalation of the trade war causing demand to weaken furth...
CapMan’s Q2 fee income of EUR 13.9m declined -7% y/y and was fairly in line with our estimate of EUR...